Supreme Court Hears Arguments on Patent Eligibility of Personalized Medicine


On December 7, 2011, the U.S. Supreme Court heard arguments in Mayo Collaborative Services v. Prometheus Laboratories, Inc. involving whether certain types of medical methods are patent-eligible subject matter. The patents at issue claim methods for optimizing patient treatment in which the level of a certain drug metabolite is measured to identify a need to increase or decrease dosage levels. The district court ruled the claims were invalid, finding the inventors’ discovery was no more than “a natural body process . . . preexisting in the patient population.” The Federal Circuit reversed, holding the claims patent-eligible because they involve a physical transformation and thus are not merely an abstract idea or law of nature. The Supreme Court remanded the case to the Federal Circuit in light of its decision in Bilski v. Kappos, after which the Federal Circuit again ruled in favor of Prometheus.

LOADING PDF: If there are any problems, click here to download the file.

Published In: Intellectual Property Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Banner & Witcoff, Ltd. | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »